Secukinumab, a novel anti-interleukin-17A antibody, exhibits low immunogenicity during long-term treatment in subjects with psoriasis

被引：0
|
作者：
Reich, K. [1 ,2 ]
Blauvelt, A. [3 ]
Armstrong, A. [4 ]
Fox, T. [5 ]
Huang, J. [5 ]
Lloyd, P. [5 ]
Bruin, G. [5 ]
机构：
[1] Dermatologikum Hamburg, Hamburg, Germany
[2] Univ Gottingen, Hamburg, Germany
[3] Oregon Med Res Ctr, Portland, OR USA
[4] Univ Colorado, Denver Sch Med, Aurora, CO USA
[5] Novartis Pharma AG, Basel, Switzerland
来源：
BRITISH JOURNAL OF DERMATOLOGY | 2014年 / 171卷 / 06期
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
P103
引用
收藏
页码：E166 / E167
页数：2
相关论文
共 50 条
  • [21] Reflectance confocal microscopy for plaque psoriasis therapeutic follow-up during an anti-interleukin-17A monoclonal antibody: an observational study
    Jiang, Qian
    Qu, Zilu
    Wang, Bei
    Jiang, Ruili
    Zhou, Yu
    Wan, Li
    Chen, Liuqing
    Hu, Feng
    SCIENTIFIC REPORTS, 2024, 14 (01):
  • [22] SECUKINUMAB, A HUMAN ANTI-INTERLEUKIN-17A MONOCLONAL ANTIBODY, SIGNIFICANTLY REDUCES PSORIASIS BURDEN IN PATIENTS WITH PSORIATIC ARTHRITIS: RESULTS FROM A PHASE 3 RANDOMIZED CONTROLLED TRIAL
    Nash, P.
    Gottlieb, A.
    Mease, P.
    McInnes, I.
    Kirkham, B.
    Kavanaugh, A.
    Rahman, P.
    Pricop, L.
    Yuan, J.
    Richards, H.
    Mpofu, S.
    INTERNAL MEDICINE JOURNAL, 2015, 45 : 42 - 42
  • [23] Secukinumab, a Human Anti-Interleukin-17A Monoclonal Antibody, Significantly Reduces Psoriasis Burden in Patients with Psoriatic Arthritis: Results from a Phase 3 Randomized Controlled Trial
    Gottlieb, Alice B.
    Mease, Philip
    McInnes, Iain B.
    Kirkham, Bruce
    Kavanaugh, Arthur
    Rahman, Proton
    Nash, Peter
    Pricop, Luminita
    Yuan, Jiacheng
    Richards, Hanno
    Mpofu, Shephard
    ARTHRITIS & RHEUMATOLOGY, 2014, 66 : S233 - S233
  • [24] Association of HLA-DRB1 alleles with clinical responses to the anti-interleukin-17A monoclonal antibody secukinumab in active rheumatoid arthritis
    Burmester, Gerd R.
    Durez, Patrick
    Shestakova, Galina
    Genovese, Mark C.
    Schulze-Koops, Hendrik
    Li, Yue
    Wang, Ying A.
    Lewitzky, Steve
    Koroleva, Irina
    Berneis, Anni Agarwal
    Lee, David M.
    Hueber, Wolfgang
    RHEUMATOLOGY, 2016, 55 (01) : 49 - 55
  • [25] Secukinumab, a novel anti-IL-17A antibody, shows low immunogenicity potential in human in vitro assays comparable to other marketed biotherapeutics with low clinical immunogenicity
    Karle, Anette
    Spindeldreher, Sebastian
    Kolbinger, Frank
    MABS, 2016, 8 (03) : 536 - 550
  • [26] Successful treatment of severe psoriasis relapse with secukinumab (interleukin 17 A inhibitor) after abrupt brodalumab (interleukin 17 receptor inhibitor) discontinuation: A retrospective study evaluating long-term efficacy and safety
    Khemis, Abdallah
    Kelati, Awatef
    Montaudie, Henri
    Lacour, Jean-Philippe
    Passeron, Thierry
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2018, 79 (04) : 758 - 760
  • [27] Infections from seven clinical trials of ixekizumab, an anti-interleukin-17A monoclonal antibody, in patients with moderate-to-severe psoriasis
    Papp, K. A.
    Bachelez, H.
    Blauvelt, A.
    Winthrop, K. L.
    Romiti, R.
    Ohtsuki, M.
    Acharya, N.
    Braun, D. K.
    Mallbris, L.
    Zhao, F.
    Xu, W.
    Walls, C. D.
    Strober, B.
    BRITISH JOURNAL OF DERMATOLOGY, 2017, 177 (06) : 1537 - 1551
  • [28] Brodalumab in the treatment of moderate-to-severe psoriasis in patients who have previously failed treatment with anti-interleukin-17A therapies
    Kimmel, Grace
    Chima, Margot
    Kim, Hee Jin
    Yao, Christopher
    Singer, Giselle
    Lebwohl, Mark
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2019, 81 (04) : AB177 - AB177
  • [29] Secukinumab exhibits a favorable safety profile during 104 weeks of treatment in subjects with moderate to severe plaque psoriasis
    Griffiths, Christopher E. M.
    Blauvelt, Andrew
    Leonardi, Craig
    Tsai, Tsen-Fang
    You, Ruquan
    Safi, Jorge
    Fox, Todd
    Reich, Kristian
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2016, 74 (05) : AB270 - AB270
  • [30] Effect of secukinumab, a fully human anti-interleukin-17a monoclonal antibody on C-reactive protein levels in patients with moderate to severe plaque psoriasis: Result of a dose-ranging study
    Langley, Richard G.
    Guettner, Achim
    Papavassilis, Charis
    Girolomoni, Giampiero
    Richards, Hanno B.
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2013, 68 (04) : AB198 - AB198
12345